ATM, CHEK2, and PTEN Genes in Breast Cancer
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.
It is known, Churpek says, that ATM and CHEK2 are considered moderate penetrants breast cancer susceptibility genes and increase the lifetime risk of disease by two- to threefold. PTEN also has known risks for breast cancer, colon cancer, endometrial cancer, and thyroid cancer.
Clinical Pearls
The panel on the study also found a woman with two bad copies of a CHEK2 mutation, which further increased her risk. In broad screenings, Churpek says that these unique situations can be identified and give more meaning to what is already known about specific gene mutations.
- ATM and CHEK2 are moderate penetrants breast cancer susceptibility genes and increase the lifetime risk of disease by two- to threefold
- PTEN also has known risks for breast cancer, colon cancer, endometrial cancer, and thyroid cancer
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
